List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7102270/publications.pdf Version: 2024-02-01



MONICALUR

#	Article	IF	CITATIONS
1	Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle, 2012, 11, 2507-2517.	1.3	110
2	Induction of miR-21 by Retinoic Acid in Estrogen Receptor-positive Breast Carcinoma Cells. Journal of Biological Chemistry, 2011, 286, 4027-4042.	1.6	82
3	Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. Journal of the Neurological Sciences, 2003, 207, 51-58.	0.3	81
4	Cell cycle effects of gemcitabine. International Journal of Cancer, 2001, 93, 401-408.	2.3	73
5	Low levels of ALS-linked Cu/Zn superoxide dismutase increase the production of reactive oxygen species and cause mitochondrial damage and death in motor neuron-like cells. Journal of the Neurological Sciences, 2005, 232, 95-103.	0.3	68
6	Cellular and molecular determinants of all― <i>trans</i> retinoic acid sensitivity in breast cancer: <i>Luminal</i> phenotype and <scp>RAR</scp> α expression. EMBO Molecular Medicine, 2015, 7, 950-972.	3.3	60
7	Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget, 2015, 6, 3394-3408.	0.8	56
8	Investigation of size, surface charge, PEGylation degree and concentration on the cellular uptake of polymer nanoparticles. Colloids and Surfaces B: Biointerfaces, 2014, 123, 639-647.	2.5	50
9	Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells. Cancer Chemotherapy and Pharmacology, 2011, 67, 369-379.	1.1	48
10	Synthesis of surfactant free PCL–PEG brushed nanoparticles with tunable degradation kinetics. International Journal of Pharmaceutics, 2013, 453, 551-559.	2.6	45
11	Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget, 2015, 6, 30072-30087.	0.8	43
12	The Molecular Assembly of Amyloid Aβ Controls Its Neurotoxicity and Binding to Cellular Proteins. PLoS ONE, 2011, 6, e24909.	1.1	39
13	Chk1-Mad2 interaction. Cell Cycle, 2013, 12, 1083-1090.	1.3	38
14	MicroRNA networks regulated by <i>all-trans</i> retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells. Oncotarget, 2015, 6, 13176-13200.	0.8	33
15	PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers. Molecular Pharmaceutics, 2016, 13, 40-46.	2.3	31
16	Heterogeneous cell response to topotecan in a CFSE-based proliferation test. Cytometry, 2004, 62A, 118-128.	1.8	30
17	Cytostatic and Cytotoxic Effects of Topotecan Decoded by a Novel Mathematical Simulation Approach. Cancer Research, 2004, 64, 2825-2832.	0.4	30
18	Biocompatible fluorescent nanoparticles for <i>in vivo</i> stem cell tracking. Nanotechnology, 2013, 24, 245603.	1.3	29

#	Article	IF	CITATIONS
19	Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells. Tumor Biology, 2014, 35, 9967-9975.	0.8	27
20	DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas. Molecular Cancer Therapeutics, 2019, 18, 1255-1264.	1.9	27
21	Human Axonal Survival of Motor Neuron (a-SMN) Protein Stimulates Axon Growth, Cell Motility, C-C Motif Ligand 2 (CCL2), and Insulin-like Growth Factor-1 (IGF1) Production. Journal of Biological Chemistry, 2012, 287, 25782-25794.	1.6	26
22	Quantitative Assessment of the Complex Dynamics of G1, S, and G2-M Checkpoint Activities. Cancer Research, 2009, 69, 5234-5240.	0.4	25
23	Poly(HPMA)-based copolymers with biodegradable side chains able to self assemble into nanoparticles. RSC Advances, 2017, 7, 50981-50992.	1.7	24
24	Neurodegeneration induced by complex I inhibition in a cellular model of familial amyotrophic lateral sclerosis. Brain Research Bulletin, 2006, 69, 465-474.	1.4	23
25	Interpreting cell cycle effects of drugs: the case of melphalan. Cancer Chemotherapy and Pharmacology, 2006, 57, 443-457.	1.1	23
26	A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma. Nanotechnology, 2014, 25, 335706.	1.3	22
27	In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models. Neoplasia, 2017, 19, 35-42.	2.3	21
28	ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. Haematologica, 2019, 104, 533-545.	1.7	21
29	Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. Oncotarget, 2015, 6, 37229-37240.	0.8	21
30	Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Oncotarget, 2016, 7, 51462-51472.	0.8	21
31	The Contribution of p53 in the Dynamics of Cell Cycle Response to DNA Damage Interpreted by a Mathematical Model. Cell Cycle, 2007, 6, 943-950.	1.3	20
32	Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma. Cancers, 2020, 12, 672.	1.7	20
33	Integrated multiplatform method for <i>in vitro</i> quantitative assessment of cellular uptake for fluorescent polymer nanoparticles. Nanotechnology, 2014, 25, 045102.	1.3	19
34	Fate of PLA and PCL-Based Polymeric Nanocarriers in Cellular and Animal Models of Triple-Negative Breast Cancer. Biomacromolecules, 2016, 17, 744-755.	2.6	19
35	Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation. Cells, 2020, 9, 1766.	1.8	19
36	S100A3 a partner protein regulating the stability/activity of RAR $\hat{1}$ ± and PML-RAR $\hat{1}$ ± in cellular models of breast/lung cancer and acute myeloid leukemia. Oncogene, 2019, 38, 2482-2500	2.6	18

#	Article	IF	CITATIONS
37	All-Trans Retinoic Acid Stimulates Viral Mimicry, Interferon Responses and Antigen Presentation in Breast-Cancer Cells. Cancers, 2020, 12, 1169.	1.7	15
38	Synthesis and characterization of pH-sensitive drinkable nanoparticles for oral delivery of ibuprofen. Nanotechnology, 2018, 29, 225604.	1.3	14
39	PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. Cancer Research, 2022, 82, 1423-1434.	0.4	14
40	Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. Oncotarget, 2015, 6, 28389-28400.	0.8	13
41	Cytotoxicity of PMMAâ€Based Nanoparticles Synthesized Adopting SDS and Tween 80. Macromolecular Symposia, 2013, 324, 134-139.	0.4	12
42	Dynamic Rendering of the Heterogeneous Cell Response to Anticancer Treatments. PLoS Computational Biology, 2013, 9, e1003293.	1.5	12
43	Magnetic domain wall tweezers: a new tool for mechanobiology studies on individual target cells. Lab on A Chip, 2016, 16, 2882-2890.	3.1	12
44	Tetracycline-regulated gene expression in the NSC-34-tTA cell line for investigation of motor neuron diseases. Molecular Brain Research, 2005, 140, 63-72.	2.5	11
45	Interoperability of time series cytometric data: A cross platform approach for modeling tumor heterogeneity. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 214-226.	1.1	11
46	Role of mitochondria and cardiolipins in growth inhibition of breast cancer cells by retinoic acid. Journal of Experimental and Clinical Cancer Research, 2019, 38, 436.	3.5	11
47	A Methyl Methacrylate– <scp>HEMA</scp> â€ <scp>CL</scp> _{<i>n</i>} Copolymerization Investigation: From Kinetics to Bioapplications. Macromolecular Bioscience, 2013, 13, 1347-1357.	2.1	10
48	Small interfering RNA delivery through positively charged polymer nanoparticles. Nanotechnology, 2016, 27, 125102.	1.3	10
49	Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells. Cancers, 2022, 14, 1807.	1.7	10
50	Timing the changes of cyclin E cell content in G1 in exponentially growing cells. Experimental Cell Research, 2003, 288, 158-167.	1.2	9
51	Selfâ€Assembling PCLâ€Based Nanoparticles as PTX Solubility Enhancer Excipients. Macromolecular Bioscience, 2018, 18, e1800164.	2.1	9
52	Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. International Journal of Molecular Sciences, 2022, 23, 5786.	1.8	9
53	Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. Targeted Oncology, 2018, 13, 235-245.	1.7	8
54	Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer. Oncotarget, 2016, 7, 15492-15506.	0.8	8

#	Article	IF	CITATIONS
55	Variability in the timing of G1/S transition. Mathematical Biosciences, 2002, 177-178, 85-101.	0.9	6
56	Preformed Biodegradable Zwitterionic Nanoparticles as Tunable Excipients for the Formulation of Therapeutics Directly at the Point of Care. Industrial & Engineering Chemistry Research, 2021, 60, 10699-10709.	1.8	6
57	Solar UV radiation: differential effectiveness of UVB subcomponents in causing cell death, micronucleus induction and delayed expression of heritable damage in human hybrid cells. International Journal of Radiation Biology, 2001, 77, 963-970.	1.0	5
58	Antiproliferative Activity of Cisplatin Detected by CFSE in p53-Proficient and p53-Deficient Cells. Immunological Investigations, 2007, 36, 847-859.	1.0	3
59	Role of cardiolipins, mitochondria, and autophagy in the differentiation process activated by all-trans retinoic acid in acute promyelocytic leukemia. Cell Death and Disease, 2022, 13, 30.	2.7	3
60	An opto-structural method to estimate the stress-strain field induced by cell contraction on substrates of controlled stiffness in vitro. Journal of Applied Biomaterials and Functional Materials, 2013, 11, 143-150.	0.7	2
61	Challenges in the Integration of Flow Cytometry and Time-Lapse Live Cell Imaging Data Using a Cell Proliferation Model. SIMAI Springer Series, 2012, , 376-398.	0.4	2
62	Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations. Cell Death and Disease, 2022, 13, .	2.7	2